Lure (France) April 4th 2024



MONTHLY INFORMATION REGARDING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING OF THE SHARE CAPITAL

as per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L'Autorité des Marchés Financiers »

	Date	Previous total number of shares making of the share capital	Previous total number of voting rights	Change explanation	New total number of shares making of the share	New total number of voting rights
FOR MORE INFORMATION, CONTACT:	31/03/2024	11.881.902	20 445 132	Fluctuation of the double voting rights	11.881.902	20 441 627

VETOQUINOL

Investor Relations

Fanny Toillon Tel.: +33 (0)3 84 62 59 88 relations.investisseurs@vetoquinol.com ABOUT VETOQUINOL



Vetoquinol is a leading global animal health company that supplies drugs and nonmedicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.

As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At June 30th 2023, Vetoquinol employs 2497 people. Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).

VETOQUINOL Magny-Vernois 70200 Lure - France

www.vetoquinol.com